Outcome and cost analysis of induction immunosuppression with IL2Mab or ATG in DCD kidney transplants

Transplantation

Volumn 97, Issue 11, 2014, Pages 1161-1165

  Popat, Reena ^a   Syed, Asim ^a   Puliatti, Carmelo ^a   Cacciola, Roberto ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

ATG; DCD; IL2Mab.; Immunosuppression; Kidney; Transplantation

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT SURVIVAL; HEALTH CARE COST; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; UNITED KINGDOM;

ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; CADAVER; GRAFT SURVIVAL; HEALTH CARE COSTS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; KIDNEY TRANSPLANTATION; PATIENT SAFETY; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; TISSUE DONORS; TREATMENT OUTCOME;

EID: 84902171857     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000442505.10490.20     Document Type: Article

References (26)

1. Akoh JA. Kidney donation after cardiac death.World J Nephrol 2012; 1: 79.
2. Cherkassky L, Lanning M, Lalli PN, et al. Evaluation of alloreactivity in kidney transplant recipients treated with antithymocyte globulin versus IL-2 receptor blocker. Am J Transplant 2011; 11: 1388.
3. Nicholson ML, Metcalfe MS, White SA, et al. A comparison of the results of renal transplantation from non-heart-beating, conventional cadaveric, and living donors. Kidney Int 2000; 58: 2585.
4. Brook NR, Waller JR, Nicholson ML. Nonheart-beating kidney donation: current practice and future developments. Kidney Inl 2003; 63: 1516.
5. Foster CE 3rd, Weng RR, Piper M, et al. Induction therapy by antithymocyte globulin (rabbit) versus basiliximab in deceased donor renal transplants and the effect on delayed graft function and outcomes. Transplant Proc 2012; 44: 164.
6. Goldsmith PJ, Ridgway DM, Pine JK, et al. Sequential transplant of paired kidneys following donation after cardiac death: impact of longer cold ischemia time on the second kidney on graft and patient outcome. Transplantation Proc 2010; 42: 3960.
7. Locke JE, Segev DL, Warren DS, et al. Outcomes of kidneys from donors after cardiac death: implications for allocation and preservation. Am J Transplant 2007; 7: 1797.
8. Nagaraja P, Roberts GW, Stephens M, et al. Influence of delayed graft function and acute rejection on outcomes after kidney transplantation from donors after cardiac death. Transplantation 2012; 94: 1218.
9. Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N EnglJ Med 2006; 355: 1967.
10. Wang W, Yin H, Li XB, et al. A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-Thymocyte globulin. Chinese Med J 2012; 125: 1135.
11. Ulrich F, Niedzwiecki S, Pascher A, et al. Long-Term outcome of ATG vs. Basiliximab induction. Eur J Clin Investig 2011; 41: 971.
12. Laftavi MR, Alnimri M, Weber-Shrikant E, et al. Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in lowrisk renal transplant recipients: 8-year follow-up. Transplant Proc 2011; 43: 458.
13. Cai J, Terasaki PI Induction immunosuppression improves longterm graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data. Transplantation 2010; 90: 1511.
14. Excellence NIfHaC. Immunosuppressive therapy for renal transplantation in adults. In: NHS, editor.: London: National Institute for Health and Clinical Excellence; 2004.
15. Aktas S, Colak T, Baskin E, et al. Comparison of basiliximab and daclizumab with triple immunosuppression in renal transplantation. Transplantation Proc 2011; 43: 453.
16. Kandus A, Arnol M, Omahen K, et al. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study. Transplantation 2010; 89: 1022.
17. Sageshima J, Ciancio G, Chen L, et al. Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation. Biologics 2009; 3: 319.
18. Vega O, Cardenas G, Correa-Rotter R, et al. Basiliximab vs. limiteddose daclizumab (2 mg/kg) administered in single or two separated doses in kidney transplantation. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 2008; 60: 82.
19. Grego K, Arnol M, Bren AF, et al. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients. Transplant Proc 2007; 39: 3093.
20. Pham K, Kraft K, Thielke J, et al. Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection. Transplant Proc 2005; 37: 899.
21. Adu D, Cockwell P, Ives NJ, et al. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-Analysis of randomised trials. BMJ 2003; 326: 789.
22. Vincenti F, Pace D, Birnbaum J, et al. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am J Transplant 2003; 3: 50.
23. Andrews PA, Emery VC, Newstead C. Summary of the British Transplantation Society Guidelines for the Prevention and Management of CMV Disease After Solid Organ Transplantation. Transplantation 2011; 92: 1181.
24. Kim JM, Jang HR, Kwon CH, et al. Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study. Transplant Proc 2012; 44: 167.
25. Martinez EG, Calabuig AS, Quesada VE, et al. Induction Treatment With Low-Dose Thymoglobulin or Basiliximab in Renal Transplants From Older Donors. Transplant Proc 2008; 40: 2900.
26. Beiras-Fernandez A, Chappell D, Hammer C, et al. Impact of polyclonal anti-Thymocyte globulins on the expression of adhesion and inflammation molecules after ischemia-reperfusion injury. Transplant Immunol 2009; 20: 224